Viking Therapeutics Shares Gain on Positive Oral Weight Loss Drug Data

Event Summary

On May 13, oral VK2735 demonstrated up to 12.2% mean weight reduction from baseline at Week 13 in Phase 2 trials. This announcement led to a gain in shares for Viking Therapeutics.